Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Diabetic Macular Edema

2,859 views

Published on

A concise and brief description of basics and pathophysiology of maculopathy in diabetes mellitus and its management

Published in: Health & Medicine
  • Be the first to comment

Diabetic Macular Edema

  1. 1. DIABETIC MACULAR EDEMA
  2. 2. OVERVIEW • Most common cause of visual loss in DM • Prevelance 11.1% (2-10%) • Incidence (10 year rate: 20.1%; 25.4%; 13.9%)
  3. 3. CLINICAL ASSOCIATONS • • • • • • • • Severity of DR Duration of diabetes and glycemic control Proteinuria, Hypertension, Dyslipidemia Pregnancy, Intraocular surgery Pan retinal photocoagulation
  4. 4. ANATOMY
  5. 5. ANATOMY
  6. 6. PATHOPHYSIOLOGY • ALDOSE REDUCTASE • VASOPROLFERATIVE FACTORS • PLATELET DYSFUNCTION
  7. 7. PATHOPHYSIOLOGY • Capillary damage and raised permeability (breakdown of inner blood retinal barrier) – Pericyte loss (oxidative damage and AGEs) – Disorganisation of tight junctions – Increased transcelluar endocytosis – VEGF – Protein kinase cβ • Microaneurysms • IRMAs
  8. 8. PATHOPHYSIOLOGY • • • • • Extracellular fluid accumulation Cystoid spaces in the outer plexiform layer May occupy entire thickness Tissue disorganisation Atrophic changes
  9. 9. PATHOPHYSIOLOGY • Hard exudates (HE): – Lipoproteinaceous deposits – Transudation – Outer plexiform layer • Subretinal fluid • Subretinal fibrosis
  10. 10. PRESENTATION • Depends on central macular involvement – Paracentral scotomas – Gradual progressive loss of vision (weeks to months) – Color vision loss – Metamorphopsia – Fluctuation of vision – Contrast sensitivity – Prolonged adaptation
  11. 11. EXAMINATION • • • • Clinically best detected by 60 D, 78 D lenses Decreased translucency Loss of foveolar reflex Patterns : – Diffuse – Focal; circinate pattern – Ischemic – Mixed
  12. 12. EXAMINATION • Stereoscopic fundus photography • Fluorescein angiography – Macular perfusion – Extent and location of capillary leakage • OCT – Documenting macular thickness – Monitoring progression
  13. 13. CSME • Retinal thickening at the center of macula • Retinal thickening and/or adjacent hard exudates at or within 500 u of center of macula • Retinal thickening ≥ 1 disc area, any part of which is within 1 DD of the center of macula
  14. 14. THERAPY • • • • • • Medical LASER photocoagulation Triancinolone acetonide Anti-VEGF therapy Protein kinase c inhibtion Vitrectomy
  15. 15. LASER photocoagulation • ETDRS gave conclusive supporting proof • Focal laser for leaking microaneurysm atleast 500 u from the fovea – (aim : closure of leak) • Grid laser for diffuse retinal thickening/ areas of ischemia – (aim : stimulate retinochoroidal pump)
  16. 16. Treatable lesions • Focal leaks >500 u from center of macula causing thickening/exudation • Focal leaks 300-500 u from center if t/t is not likely to damage perifoveal capillary network • Areas of diffuse leakage • Abnormal avasular zone
  17. 17. ETDRS protocol Focal Spot size Exposure time Grid 50-100 u <200u 0.05 – 0.1 s Intensity Whitening/darkening of microaneurysms (80 - 120 mW) 80 – 180 mW Number of burns Coagulate all leaking foci All zones of diffuse leakage Placement 500 – 3000 u from center sparing papillomacular bundle Sessions 1 Argon green laser (514 nm) and Goldmann 3 mirror lens Avoid argon blue-green (488 nm) Follow up after 4 weeks, if lesions missed then treat after 4 months Spacing is one burn width apart
  18. 18. LASER photocoagulation • Adverse effects – Foveal burns – Subretinal hemorrhage – Vitreous hemorrhage – RPE creep – CNV – Paradoxically increased HE
  19. 19. TRIANCINOLONE ACETONIDE • • • • Intravitreal route Needs repeated injections Duration of effect : 2-3 months with 4mg Complications – Raised iop – Endophthalmitis – Cataracts • Peribulbar route
  20. 20. ANTI-VEGF therapy • Bevacizumab (Avastin) • Ranibizumab (Lucentis) – – – – Fusion proteins with human antibody backbone Bind all VEGF subtypes Intravitreal route No definite schedule • Pegaptinib (Macugen) – Engineered RNA fragment – Specific sites for VEGF binding
  21. 21. PROTEIN KINASE C Inhibitors • PKCβ – Ruboxistaurin – Oral administration

×